| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Jean Hailes Foundation (S.L.D., R.B., S.R.D.), Clayton, Victoria 3168, Australia; Department of Biochemistry (S.L.D.), National Health and Medical Research Council Centre of Clinical Research Excellence (R.B., S.D., S.R.D.), and Department of Obstetrics and Gynaecology (R.B., S.R.D.), Monash University, Clayton, Victoria 3800, Australia; and Mayne Health Dorevitch Pathology (J.G.M.), Melbourne, Australia, Victoria 3078, Australia
Address all correspondence and requests for reprints to: Dr. Sonia Davison, Women’s Health Program, Monash Medical School, Alfred Hospital, Commercial Road, Prahran, Victoria 3181, Australia. E-mail: Womens.Health{at}med.monash.edu.au.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Objective: The objective of this study was to document the effects of age on androgen levels in healthy women and to explore the effects of natural and surgical menopause.
Design, Setting, and Participants: A cross-sectional study was conducted of 1423 non-healthcare-seeking women, aged 18–75 yr, randomly recruited from the community over 15 months.
Main Outcome Measures: Serum levels by age of total testosterone (T), calculated free T, dehydroepiandrosterone sulfate, and androstenedione in a reference group of women free of confounding factors. Women in the reference group had no usage of exogenous steroid therapy; no history of tubal ligation, hysterectomy, or bilateral oophorectomy; and no hyperprolactinemia or polycystic ovarian syndrome. The effects of natural and surgical menopause on sex steroid levels were also examined.
Results: In the reference population (n = 595), total T, calculated free T, dehydroepiandrosterone sulfate, and androstenedione declined steeply with age (P < 0.001), with the decline of each being greater in the earlier than the later decades. Examination of serum androgen levels by year in women aged 45–54 yr showed no independent effect of menopausal status on androgen levels. In women aged 55 yr or older, those who reported bilateral oophorectomy and were not on exogenous steroids had significantly lower total T and free T levels than women 55 yr or older in the reference group.
Conclusions: We report that serum androgen levels decline steeply in the early reproductive years and do not vary because a consequence of natural menopause and that the postmenopausal ovary appears to be an ongoing site of testosterone production. These significant variations in androgens with age must be taken into account when normal ranges are reported and in studies of the role of androgens in women.
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
There is growing interest in the role for androgen therapy for women, specifically T and the adrenal preandrogen dehydroepiandrosterone (DHEA). DHEA is sold over the counter in the United States, and inclusion of T in postmenopausal hormone therapy regimens is becoming more widespread. T preparations specifically for use in women are now undergoing phase 3 clinical trials, hence the need for age-specific validated normal ranges of the most commonly measured androgens in women as an initial basis for exploring the consequences of a woman having levels outside the age-specific range.
We have measured serum androgen levels in a large community-based group of women aged from the early reproductive years to many years post menopause to describe normative ranges by decade for total T, calculated free T, DHEA-sulfate (DHEAS) and androstenedione. To study normal physiology, we report androgen levels by decade in a reference group of women who were free of factors known to modify androgen levels. We have also explored the effects of natural and surgical menopause on the levels of these androgens.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Participants were women aged 18–75 yr, recruited from April 2002 until August 2003 from Australia’s southeastern state of Victoria, which according to the 2001 census, had a female population of approximately 1.9 million over the age of 15 yr. A database of eligible women was created using the following methodology: women were recruited by telephone using a database of individuals from household addresses selected at random on a weekly basis from Australian electoral areas. In Australia, because voting is compulsory, every adult must be registered on the electoral roll. Each electoral area was divided into sampling points of approximately equal numbers of 25,000 each. Melbourne had 105 sampling points, and country Victoria had 43 sampling points. Starting addresses were selected at random from the electoral roll for each of the sampling points. Interviews were conducted in person on Saturdays and Sundays between 0900 and 1600 h. Eight interviews were conducted per sampling point. Only one eligible person was recruited per household, and people recruited to the sample tend to stay on the active database for about 2 yr. For this study, the database as of May 2002 was used initially, with eventual inclusion of past members of the database, back to 1998, to recruit sufficient women to the study.
Women from the database underwent telephone screening. Women were excluded if they were pregnant or less than 6 wk postpartum or had experienced any of the following in the preceding 3 months: an acute psychiatric illness; acute renal, liver, cardiovascular disease or any other acute major illness; gynecological surgery; or active malignancy or cancer treatment, excluding nonmelanotic skin cancer.
Eligible participants were asked to attend for a single morning fasting blood test and measurement of height (centimeters), weight (kilograms), and waist and hip circumference (centimeters). Premenopausal women attended after d 8 in the cycle to avoid the early follicular phase nadir of testosterone production. The women completed a personal profile questionnaire consisting of questions about general demographic details, menstrual pattern, acne, hirsutism, past gynecological surgery, current medical and psychiatric treatment, exercise, and alcohol and tobacco use.
The study protocol was approved by the Human Research and Ethics Committee, Southern Health, Clayton, Australia, and all participants provided written informed consent.
Sample size. This work is part of a study of the relationship of androgens and sexual function. The original sample size was related to the primary hypothesis for that study. The findings from this aspect of the study will be reported separately.
Definition of the reference group
We defined the reference group of women from within the study population to establish normative androgen values by decade. Subjects were excluded from the reference group if any of the following applied: use of exogenous steroid therapy (estrogen- and/or progestin-containing contraceptive agents of any delivery method, postmenopausal hormone therapy including topical or vaginal preparations, androgens, antiandrogens, or glucocorticoid or mineralocorticoid agents), bilateral oophorectomy, hysterectomy, tubal ligation, hyperprolactinemia (prolactin > 550 mIU/liter; normal range, 50–500 mIU/liter), or polycystic ovarian syndrome (PCOS). PCOS was defined by a woman having at least two clinical features of this condition: self-reported menstrual irregularity or hirsutism; LH-to-FSH ratio greater or equal to 2:1; SHBG less than 30 nmol/liter (normal range, 27–109 nmol/liter), and free androgen index (total T/SHBG x 100) greater than 4.5% (normal range, 1.0–4.5%).
Effect of bilateral oophorectomy on androgen levels
We compared serum androgen levels of women who reported a bilateral oophorectomy and were otherwise comparable with women in the reference group (normoprolactinemia, and not taking exogenous systemic steroids of any form) with values determined for the women in the reference group.
Definition of menopause
Menopausal status was based on the responses to the personal profile questionnaire about cessation of menses or time of vasomotor symptom onset in the case of hysterectomy. Because determination of menopausal status was not clear-cut in some instances, we used a decision tree for classification. In consecutive order, we looked at whether women were aged less than 55 or 55 yr and older, stated an age at menopause, had regular menses or not, and whether they were on the oral contraceptive pill or hormone therapy. Finally, we looked at FSH and estradiol levels to decide the menopausal classification
Laboratory procedures
Fasting serum samples were stored at –80 C until assayed. Analysis of serum for all hormones was performed in the Clinical Biochemistry Department of Mayne Health Dorevitch Pathology Laboratory, Melbourne, Victoria, Australia.
Total T was measured by a direct manual RIA method (Biosource Europe S.A., Nivelles, Belgium) using antibody-coated tubes and iodine-labeled T tracer (500 µl). Mean between-batch coefficients of variation (CV) were 12.8, 9.7, 8.8, and 7.1% at 0.17, 0.61, 1.77, and 11.5 nmol/liter (n = 100), respectively; mean within-batch CV were 10.5, 5.3, 4.2, and 4.7% at the same concentrations (n = 20). This methodology was validated against a widely published conventional RIA that included organic solvent (ethylacetate:hexane, 3:2) extraction and Celite column partition chromatography before RIA (6) in 259 of the study samples. The direct manual RIA for testosterone used in this study has also previously been validated against the process of equilibrium dialysis in men and postmenopausal women (7). Samples with T values less than 0.2 nmol/liter were reported as less than 0.2 nmol/liter, but for statistical analysis we assigned these a value of 0.1. Free T was calculated using the Sodergard equation (8). SHBG and DHEAS were measured by a solid-phase, two-site chemiluminescent enzyme immunometric assay using the Immulite automated analyzer (Diagnostic Products Corp., Los Angeles, CA). The intra- and interassay CV for SHBG are 6.5 and 8.7%, respectively; the detection limit is 0.2 nmol/liter. For DHEAS, the intraassay CV is 6.8–9.5%, and interassay CV is 9.2–12.7%. Androstenedione was measured by direct RIA (DSL Inc., Webster, TX). Interassay CV is 5.8–10.4%.
Statistical analysis
Serum levels of total T, calculated free T, DHEAS, and androstenedione were reported for the reference group by decade as mean (SD), median, minimum, maximum, and 10th and 90th percentiles. For the descriptive analysis, participants were divided into six age groups: 18–24, 25–34, 35–44, 45–54, 55–64, and 65–75 yr. The first three groups therefore consisted of women who were mostly premenopausal, the final two groups represented women in the postmenopausal state, and the group aged 45–54 yr included both pre- and postmenopausal women. The youngest age group represents an incomplete decade because recruitment was limited to women 18 yr and above. The relationships between androgens and age are presented graphically as scatter plots and box and whisker plots and, in the case of SHBG, a fitted Lowess curve (a means of fitting a smooth nonparametric regression curve to a scatter plot).
Linear regression was used to model independent determinants of serum levels of androgens, including age measured in years and menopausal status. We also explored the effect of menopause on androgen levels by presenting androgen levels per individual year for women in the age group 45–54 yr, in which decade there were sufficient numbers of both pre- and postmenopausal women for comparison. The effect of oophorectomy on androgens was assessed using the t test for independent means; this was reported in women older than 55 yr to limit the confounding effect of age and because the older age groups included sufficient numbers of women who had undergone oophorectomy. All reported P values are two sided with significance defined as P < 0.05. Analyses were performed with SPSS statistical software (version 11.5; SPSS Australasia Pty. Ltd., North Sydney, Australia) or STATA statistical software (version 8.0, Stata Corp, College Station, TX).
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
). Of these, 80% were Australian born, and fewer than 2% of the whole group were non-Caucasian. A total of 595 women fulfilled the criteria for the reference group (Table 1). The mean age (SD) of the reference group was 48.5 (14.2) yr, and their mean body mass index (BMI) (SD) was 27.4 (6.9) kg/m2. For weight, BMI, smoking, and parity the reference group reflected the total study population from which they were drawn. However, because of the difficulty recruiting younger women to the study and the prevalence of use of the oral contraceptive pill among young women, there were only 22 women less than 25 yr old who were eligible for the reference group.
|
|
and 3 and Fig. 2). The decline with age is such that the mean total T indicates a decline by 55% between the youngest and oldest groups. Similar comparisons between the two extremes of age demonstrated a fall in mean free T by 49%, a fall in mean DHEAS by 77%, and a fall in mean androstenedione by 64%. The regression coefficients for age in linear regression models for each androgen level are negative and significantly different from zero (P < 0.001). The r2 values indicate that age explains between 30.8% (DHEAS) and 12.1% (free T) of the variation seen in the serum levels of the hormones. SHBG does not appear to vary over the first five decades of adult life and increases minimally in the age group 65–75 yr (Fig. 3). A Lowess curve was used to describe the changes in SHBG in later years that would not be captured by a linear model.
|
|
|
|
We investigated whether menopause makes a contribution to the determination of androgen levels independent of age. The inclusion of a dichotomous term for menopausal status in the regression equations for the serum levels of the androgens does not improve the proportion of the variation explained, and the regression coefficient for the menopause term was never significant at the 5% level. Plots of the levels of each of the steroids for premenopausal (n = 88) and postmenopausal (n = 52) women by individual year of age between 45 and 54 yr indicates that there is no apparent difference between women who are pre- or postmenopausal at any age in this interval (Fig. 4).
|
). Similarly, for the age group 65–75 yr, total T levels are 0.39 (0.22) and 0.71 (0.48) nmol/liter (P = 0.01), and free T levels are 6.06 (3.33) and 9.76 (6.92) pmol/liter (P = 0.04) for oophorectomized vs. reference-group women, respectively. Although there is a trend toward lower levels, there are no statistically significant differences in DHEAS or androstenedione between oophorectomized women aged 55–75 yr and women in the reference group. We examined our data for evidence that hysterectomy or tubal ligation are each associated with differences in serum levels of androgens. The differences between groups of women who did and did not report these procedures did not achieve statistical significance at the 5% level but suggested a decline in all androgens with each of these procedures. |
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
To explore normal physiology, we eliminated the effects of factors known to modulate androgen levels in women and thus achieved a reference group of 595 women for this study, derived from a large group of non-healthcare-seeking women recruited from the community. Over 3000 women agreed to participate in this study; however, 1423 women completed the study, most likely because of the requirement for attendance at a pathology laboratory for a fasting, morning blood sample (measurement of lipid profiles was a subproject of this study) and completion of questionnaires of a personal nature. Although a large number of younger women agreed to participate in this study, relatively few completed the study, most likely because of the inconvenience of having to attend for a fasting blood sample linked to menstrual cycle phase. A high nonparticipation rate is a price paid for population-based recruitment. A convenience sample could have been used to improve the participation rate but could also have biased the results. Our sample being mostly Caucasian is reflective of the Australian population. It remains to be established whether our findings reflect the changes in women of differing ethnicity.
Several women in the reference group had androgen levels that would suggest pathophysiological androgen excess. These women denied use of androgenic steroid hormone preparations and had no history of acne, hirsutism, or PCOS, and we could find no reason to exclude them from the analysis. These observations reconfirm that even within a so-called normal population there is a wide range of normality.
The decline in free and total T in the early premenopausal years that we have reported is not novel. Zumoff et al. (1) reported lower mean 24-h values for total and calculated free T among older vs. younger reproductive aged women (n = 33 women), and others have reported loss of the midcycle rise in free T that characterizes the menstrual cycle in young ovulating women in the later reproductive years (9). However, this is the first study to demonstrate the early age-related decline of total T, free T, DHEAS, and androstenedione in the context of the full adult female life span. The extent to which this decline reflects aging ovarian function or the decline in adrenal precursor steroids needs to be determined.
When we compared hormone levels between premenopausal and postmenopausal women of the same age, there was no effect of the menopause transition. Rather, the higher androgen levels in premenopausal compared with postmenopausal women in this reference group reflects the strong effect of age. This is in keeping with previous data (10).
Whether the postmenopausal ovary has significant endocrine activity is somewhat controversial. Reductions in T and androstenedione have been demonstrated after oophorectomy (11, 12), although more recently, Couzinet et al. (13) reported that the postmenopausal ovary is not a source of significant androgen production. This study indicates lower levels of total and free T, but not DHEAS or androstenedione, among older postmenopausal women with previous bilateral oophorectomy, suggesting ongoing ovarian production of androgens many years beyond the time of natural menopause. In addition, a late elevation in total and calculated free T and androstenedione was suggested by the regression models within the reference group, consistent with previous reports (14, 15, 16). This cannot be explained by changing SHBG levels but may represent an increase in ovarian androgen production via stimulation of ovarian theca cells by elevated levels of LH long after the menopause. We were not able to comment on the difference between androgen levels in oophorectomized vs. reference-group women younger than 55 yr, because of insufficient numbers of younger oophorectomized women in this community-based sample.
The decline of adrenal DHEA and DHEAS with age that we have observed has been described by others (2, 17), but the mechanism underlying this is unclear. An alteration in adrenal zonation, such that the zona reticularis is of lesser mass with advancing age, has been described (18). Additional studies are necessary to determine the cause and mechanism of the seemingly selective loss of zona reticularis mass and to confirm this process occurs with both female and male aging.
The slightly higher SHBG levels seen in the oldest women in this study contrasts with the findings of Burger et al. (5), who reported a decrease across the menopause transition, and also with Gambera et al. (19), who reported a decline in SHBG levels with advancing age. Maruyama et al. (20) reported an increase in SHBG with age, such that levels in women in their 80s were double those of women in their 20s. The larger number of women in this study compared with the other studies may explain the difference in findings for SHBG.
Our findings of a statistically nonsignificant decline in androgen levels after hysterectomy and tubal ligation is in keeping with the findings of Laughlin et al. (14, 15, 16), who reported significantly lower levels of androstenedione and total T in women who had previously undergone hysterectomy, although this study was restricted to women aged 50–89 yr.
This study provides normative data for the specific assays used and for free T levels calculated using the Sodergard equation. Levels of free T calculated using this equation have been demonstrated to correlate strongly with levels measured by equilibrium dialysis (7, 21, 22). Because measurements vary between assays as a result of methodology and the antibodies employed, these values should not be considered absolute but rather a guide to the degree of change one would expect to observe using other validated methods. Because of the cross-sectional design of this study, we cannot be certain that the changes we have described occur in any given individual with age, although this is highly probable. The collection of prospective, longitudinal data would require much greater numbers, because it would be limited by common medical and surgical interventions, and would be a major undertaking in terms of logistics, cost, and compliance.
In summary, serum androgen levels decline with age from the early reproductive years, do not vary with the menopause transition, and with the exception of the preandrogen DHEAS, increase slightly during the seventh decade.
From a clinical perspective, this report provides physiological reference ranges that are an essential basis for further investigation into female androgen insufficiency or excess.
|
Footnotes |
|---|
First Published Online April 12, 2005
Abbreviations: BMI, Body mass index; CV, coefficient(s) of variation; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; PCOS, polycystic ovary syndrome; T, testosterone.
Received January 31, 2005.
Accepted April 4, 2005.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  G. Secreto, E. Venturelli, E. Meneghini, M. Greco, C. Ferraris, M. Gion, M. Zancan, A. S.C. Fabricio, F. Berrino, A. Cavalleri, et al. Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 2942 - 2948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Laghi, N. Adiguzel, and M. J. Tobin Endocrinological derangements in COPD Eur. Respir. J., October 1, 2009; 34(4): 975 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Wylie and F Malik Review of drug treatment for female sexual dysfunction Int J STD AIDS, October 1, 2009; 20(10): 671 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. D. Shaw, S. S. Srouji, S. N. Histed, K. E. McCurnin, and J. E. Hall Aging Attenuates the Pituitary Response to Gonadotropin-Releasing Hormone J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3259 - 3264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.F.R. Sowers, H. Zheng, D. McConnell, B. Nan, C.A. Karvonen-Gutierrez, and J.F. Randolph Jr Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging Hum. Reprod., September 1, 2009; 24(9): 2276 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Broekmans, M. R. Soules, and B. C. Fauser Ovarian Aging: Mechanisms and Clinical Consequences Endocr. Rev., August 1, 2009; 30(5): 465 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A E Wluka, F Hanna, M Davies-Tuck, Y Wang, R J Bell, S R Davis, J Adams, and F M Cicuttini Bone marrow lesions predict increase in knee cartilage defects and loss of cartilage volume in middle-aged women without knee pain over 2 years Ann Rheum Dis, June 1, 2009; 68(6): 850 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Testosterone patches for female sexual dysfunction DTB, March 1, 2009; 47(3): 30 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Marnach and P. M. Casey Understanding Women's Sexual Health: A Case-Based Approach Mayo Clin. Proc., December 1, 2008; 83(12): 1382 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Davis, M. Moreau, R. Kroll, C. Bouchard, N. Panay, M. Gass, G. D. Braunstein, A. L. Hirschberg, C. Rodenberg, S. Pack, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen N. Engl. J. Med., November 6, 2008; 359(19): 2005 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Cussons, G. F. Watts, V. Burke, J. E. Shaw, P. Z. Zimmet, and B. G.A. Stuckey Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome Hum. Reprod., October 1, 2008; 23(10): 2352 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Wijayaratne, A. J. Teichtahl, A. E. Wluka, F. Hanna, R. Bell, S. R. Davis, J. Adams, and F. M. Cicuttini The determinants of change in patella cartilage volume--a cohort study of healthy middle-aged women Rheumatology, September 1, 2008; 47(9): 1426 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brown Skeletal muscle and bone: effect of sex steroids and aging Advan Physiol Educ, June 1, 2008; 32(2): 120 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Davis, M.-A. Papalia, R. J. Norman, S. O'Neill, M. Redelman, M. Williamson, B. G.A. Stuckey, J. Wlodarczyk, K. Gard'ner, and A. Humberstone Safety and Efficacy of a Testosterone Metered-Dose Transdermal Spray for Treating Decreased Sexual Satisfaction in Premenopausal Women: A Randomized Trial Ann Intern Med, April 15, 2008; 148(8): 569 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Davis, S. M. Shah, D. P. McKenzie, J. Kulkarni, S. L. Davison, and R. J. Bell Dehydroepiandrosterone Sulfate Levels Are Associated with More Favorable Cognitive Function in Women J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 801 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mah, D. B. Seligson, A. Li, D. C. Marquez, I. I. Wistuba, Y. Elshimali, M. C. Fishbein, D. Chia, R. J. Pietras, and L. Goodglick Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer Cancer Res., November 1, 2007; 67(21): 10484 - 10490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.G. Burger, G.E. Hale, D.M. Robertson, and L. Dennerstein A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project Hum. Reprod. Update, November 1, 2007; 13(6): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Fogle, F. Z. Stanczyk, X. Zhang, and R. J. Paulson Ovarian Androgen Production in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3040 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Panjari and S. R. Davis DHEA therapy for women: effect on sexual function and wellbeing Hum. Reprod. Update, May 1, 2007; 13(3): 239 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Potter A 60-Year-Old Woman With Sexual Difficulties JAMA, February 14, 2007; 297(6): 620 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Cappola, S. J. Ratcliffe, S. Bhasin, M. R. Blackman, J. Cauley, J. Robbins, J. M. Zmuda, T. Harris, and L. P. Fried Determinants of Serum Total and Free Testosterone Levels in Women over the Age of 65 Years J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Basaria and A. S. Dobs Controversies Regarding Transdermal Androgen Therapy in Postmenopausal Women J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4743 - 4752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Morrison, R. D. Brinton, P. J. Schmidt, and A. C. Gore Estrogen, Menopause, and the Aging Brain: How Basic Neuroscience Can Inform Hormone Therapy in Women J. Neurosci., October 11, 2006; 26(41): 10332 - 10348. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wierman, R. Basson, S. R. Davis, S. Khosla, K. K. Miller, W. Rosner, and N. Santoro Androgen Therapy in Women: An Endocrine Society Clinical Practice Guideline J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3697 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Jankowski, W. S. Gozansky, R. S. Schwartz, D. J. Dahl, J. M. Kittelson, S. M. Scott, R. E. Van Pelt, and W. M. Kohrt Effects of Dehydroepiandrosterone Replacement Therapy on Bone Mineral Density in Older Adults: A Randomized, Controlled Trial J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2986 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.K. Welt, Y. Jimenez, P.M. Sluss, P.C. Smith, and J.E. Hall Control of estradiol secretion in reproductive ageing Hum. Reprod., August 1, 2006; 21(8): 2189 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. I. Leibel, E. E. Baumann, M. Kocherginsky, and R. L. Rosenfield Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1275 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Rochira, A Balestrieri, B Madeo, L Zirilli, A R M Granata, and C Carani Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology Eur. J. Endocrinol., February 1, 2006; 154(2): 175 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Arlt Androgen therapy in women Eur. J. Endocrinol., January 1, 2006; 154(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Singh, M. L. Lee, I. Sinha-Hikim, M. Kushnir, W. Meikle, A. Rockwood, S. Afework, and S. Bhasin Pharmacokinetics of a Testosterone Gel in Healthy Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 136 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhasin Female Androgen Deficiency Syndrome--An Unproven Hypothesis J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4970 - 4972. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Davis, S. L. Davison, S. Donath, and R. J. Bell Circulating Androgen Levels and Self-reported Sexual Function in Women JAMA, July 6, 2005; 294(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
